After Bayer offloaded its diabetes device unit last month, some investors thought Roche would follow suit and sell its own underperforming diabetes diagnostics business. The Swiss drugmaker has experienced its fair share of problems with the unit, which stalled recently in light of price cuts and reimbursement issues in the U.S. But anyone expecting a sale of Roche's diabetes diagnostics business shouldn't hold their breath, analysts said.
We need your help to ferret out the best, most timely examples of med tech innovation. Who has ambition and the potential to make a real leap forward, while being wildly appealing to physicians, patients and payers across a global healthcare environment that is increasingly value-based?
Hedge fund managers are so flush that now they're giving money away. A pair of prominent fund heads have led a collection of wealthy individuals to back a project at the Broad Institute of MIT and Harvard researching the bacteria behind tuberculosis with $20 million. The goal is to better understand the bacteria itself, as well as how drug resistance forms in it and to develop a rapid diagnostic test for drug-resistant TB.
Medical products company Hill-Rom is using its $2 billion acquisition of patient monitoring and diagnostics player Welch Allyn to decrease its reliance on sales of large, acute-care capital equipment--which are highly subject to pressure from macroeconomic changes.
Researchers at Texas A&M University are developing a methodology to detect tuberculosis in 10 minutes, rather than days.
On the heels of a $47 million settlement with the Department of Justice regarding questionable kickbacks, blood testing diagnostic company HDL has filed for Chapter 11 bankruptcy.
Melbourne, Australia-based Global Kinetics expects that its Personal KinetiGraph can offer a better way for physicians to monitor the progression of Parkinson's disease and other movement disorders in patients and to see how the disease symptoms respond to specific treatments. The device provides an objective, continuous quantification of movement disorder symptoms.
Royal Philips and the Academic Medical Center in Amsterdam, the Netherlands, will collaborate in a European multicenter trial of a new diagnostic technique to assess the results of minimally invasive treatment for diabetic foot and critical limb ischemia. The trial is slated to start this summer with final results expected in 2017.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
London-based Abcodia expects a U.S. and U.K. launch this year of its ovarian cancer screening test that's been found to be twice as effective as the testing that's currently standard. After releasing data on the ROCA test earlier this month, now it's raised £5.25 million ($8 million) to get through those goals.